TNON Company Profile and Key Details

Tenon Medical, Inc. has 8.88 million shares outstanding. The public float is 8.23 million shares, elevated short interest at 7.19% of float. This equals 636.50 thousand shares. The short ratio is 0.06 days. Institutional investors hold 2.82% of the float. Insiders own 13.18%. Grawey Nathaniel A. holds 101.17 thousand shares, VAN DICK STEVEN M has 100.42 thousand shares and GINN RICHARD has 85.32 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

TNON has shown mixed momentum, gaining 1.88% over the past week and -21.69% over the past quarter, though year-to-date performance is up 2.05%. Short-term trend indicators are bullishly aligned (SMA20 -24.94%, SMA50 -32.97%, SMA200 -40.03%). The stock’s 14-day RSI is 19.44 (weak momentum), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -88.53% below its high and over 0.8% above its low. Average 10-day trading volume of 151.39 thousand shares is slightly above the 3-month average of 102.36 thousand, indicating heightened recent market interest.

Tenon Medical, Inc. generated EPS of -$2.76 over the past year. Five-year average earnings growth is -25.43%. Wall Street analysts project EPS growth of 59.74% annually over the next five years. The latest quarter delivered EPS of -$0.40. The next quarter is forecast at -$0.36. Next year's EPS is expected at $62.98. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 347.76% upside. The low target suggests 347.76% downside. The mean target is $3.00. This offers 347.76% upside. Tenon Medical, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by 29.03%. The prior quarter beat by -23.4%. Over the last six quarters, Apple has recorded several small beats. These include -5.56% in August 13, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Tenon Medical, Inc. (NASDAQ:TNON) closed at $0.67 USD, gaining $0.01 (0.80%) from the previous close of $0.67. The stock is currently within 5% of its 52-week low $0.64 and $5.85. With a market capitalization of about $5.78 million, Tenon Medical, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.28). Key stats such as the average daily volume over the past year has been around 158.50 thousand shares, in line with its 52-week average. Headquartered in Los Gatos, CA, Tenon Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Steven Foster, the company employs approximately 27 people and listed since April 27, 2022. Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and corresponding outcomes.

Tenon Medical, Inc. trades at a P/E ratio of -0.43, slightly below the S&P 500 average, with a price-to-sales ratio of 1.79 and a price-to-book ratio of 1.15 suggesting the stock is closer to book value. The P/FCF stands at -0.51, also above market averages.

Our AI price prediction model suggests that Tenon Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -18.06%, with price expected at $0.55 by February 20, 2026, within a range of $0.50 to $0.60 3-Month Outlook: Projected fall of -74.67%, reaching $0.17 by May 07, 2026, with a range of $0.03 to $0.28. 1-Year Outlook: Projected loss of -88.08%, with price at $0.08 by February 05, 2027, within a range of $0.00 to $1.91.

Tenon Medical, Inc. (NASDAQ:TNON) shares are flat 2.05% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tenon Medical, Inc. trading at a premium to the broader market with a P/E of -0.43. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.00, suggesting 644.93% upside. Our AI forecast model points to short-term weakness (-18.06% over two weeks), a medium-term fall (-74.67% over three months), and a longer-term loss (-88.08% over one year), with expected trading ranges indicating moderate volatility.